MDGL vs. NBIS
MDGL (Madrigal Pharmaceuticals, Inc.) and NBIS (Nebius Group N.V.) are both stocks. MDGL operates in Biotechnology (Healthcare), while NBIS operates in Internet Content & Information (Communication Services). Over the past year, MDGL returned 62.66% vs 393.02% for NBIS. At a 0.25 correlation, their price movements are largely independent.
Performance
MDGL vs. NBIS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDGL achieves a -17.44% return, which is significantly lower than NBIS's 177.59% return.
MDGL
- 1D
- 1.37%
- 1M
- -10.95%
- YTD
- -17.44%
- 6M
- -15.87%
- 1Y
- 62.66%
- 3Y*
- 21.44%
- 5Y*
- 34.82%
- 10Y*
- 46.09%
NBIS
- 1D
- 4.55%
- 1M
- 5.65%
- YTD
- 177.59%
- 6M
- 164.98%
- 1Y
- 393.02%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
MDGL vs. NBIS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
MDGL Madrigal Pharmaceuticals, Inc. | -17.44% | 88.72% | 46.61% |
NBIS Nebius Group N.V. | 177.59% | 202.18% | 46.25% |
Correlation
The correlation between MDGL and NBIS is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Oct 18, 2024 | 0.25 |
Fundamentals
MDGL:
$13.96B
NBIS:
$71.79B
MDGL:
-$12.87
NBIS:
$3.17
MDGL:
10.21
NBIS:
69.73
MDGL:
25.68
NBIS:
9.91
MDGL:
$1.13B
NBIS:
$877.90M
MDGL:
$1.05B
NBIS:
$420.60M
MDGL:
-$287.63M
NBIS:
-$52.78M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDGL vs. NBIS — Risk / Return Rank
MDGL
NBIS
MDGL vs. NBIS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Nebius Group N.V. (NBIS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDGL | NBIS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.15 | ||
| Sortino ratioReturn per unit of downside risk | -1.55 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.42 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 2.11 | 8.03 | -5.91 |
| Martin ratioReturn relative to average drawdown | 4.63 | 18.34 | -13.71 |
Loading charts...
Drawdowns
MDGL vs. NBIS - Drawdown Comparison
The maximum MDGL drawdown since its inception was -98.40%, which is greater than NBIS's maximum drawdown of -58.27%. Use the drawdown chart below to compare losses from any high point for MDGL and NBIS.
Loading charts...
Drawdown Indicators
| MDGL | NBIS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.40% | -58.27% | -40.13% |
Max Drawdown (1Y)Largest decline over 1 year | -29.36% | -45.47% | +16.11% |
Max Drawdown (3Y)Largest decline over 3 years | -52.88% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -61.41% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -82.19% | — | — |
Current DrawdownCurrent decline from peak | -20.25% | -12.15% | -8.10% |
Average DrawdownAverage peak-to-trough decline | -58.52% | -18.94% | -39.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.38% | 19.86% | -6.48% |
Volatility
MDGL vs. NBIS - Volatility Comparison
The current volatility for Madrigal Pharmaceuticals, Inc. (MDGL) is 13.71%, while Nebius Group N.V. (NBIS) has a volatility of 30.23%. This indicates that MDGL experiences smaller price fluctuations and is considered to be less risky than NBIS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDGL | NBIS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.71% | 30.23% | -16.52% |
Volatility (6M)Calculated over the trailing 6-month period | 31.76% | 71.43% | -39.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.97% | 104.41% | -58.44% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 133.37% | 110.20% | +23.17% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 117.49% | 110.20% | +7.29% |
Dividends
MDGL vs. NBIS - Dividend Comparison
Neither MDGL nor NBIS has paid dividends to shareholders.
Financials
MDGL vs. NBIS - Financials Comparison
This section allows you to compare key financial metrics between Madrigal Pharmaceuticals, Inc. and Nebius Group N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MDGL and NBIS have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIS has higher volatility (30.23%) compared to MDGL (13.71%). In terms of maximum drawdown, MDGL dropped -98.40% vs NBIS's -58.27%.
NBIS currently has the higher Sharpe Ratio (3.50 vs 1.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDGL and NBIS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer